Stockreport

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled to discuss deve [Read more]